Back

The AMPK activator A-769662 inhibits human TASK3 potassium channels in an AMPK-independent manner

Said, E. A.; Lewis, R. W.; Dallas, M. L.; Ross, F. A.; evans, a. m.

2022-05-25 pharmacology and toxicology
10.1101/2022.05.24.493214 bioRxiv
Show abstract

Heteromeric TASK1/3 channels play a fundamental role in oxygen-sensing by carotid body type 1 cells, where hypoxia-induced inhibition of TASK3 and/or TASK1/3 potassium currents leads to depolarisation, voltage-gated calcium entry, exocytotic transmitter release and increases in carotid body afferent input responses that initiate corrective changes in breathing patterns. However, the mechanism by which hypoxia leads to TASK-1/3 channel inhibition is still debated. It had been proposed that the AMP-activated protein kinase (AMPK) might directly phosphorylate and inhibit TASK channels, in particular TASK-3, although subsequent studies on rat type I cells argued against this view. Here we report on the effects of novel, highly selective AMPK activators on recombinant human TASK-3 potassium channels. Sequence alignment identified an AMPK recognition motif in TASK-3, but not TASK-1, with Ser55 representing a potential site for AMPK-dependent phosphorylation in TASK-3. However, neither of the AMPK activators, AICAR or MK-8722, caused a significant reduction of human TASK-3 current amplitude. By contrast, high concentrations of the AMPK activator A-769662 (100-500 {micro}M) inhibited human TASK-3 currents in a concentration-dependent manner. Importantly, A-769662 (300 {micro}M) also inhibited human TASK-3 channels in HEK293 cells that stably over-expressed an AMPK-{beta}1 subunit mutant (S108A) that renders AMPK insensitive to activators binding the Allosteric Drug and Metabolite (ADaM) site, such as A-769662. We therefore identify A-769662 as a novel human TASK-3 channel inhibitor and provide conclusive evidence that AMPK does not regulate TASK-3 channel currents.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
eLife
5422 papers in training set
Top 1%
18.3%
2
British Journal of Pharmacology
34 papers in training set
Top 0.1%
8.2%
3
Scientific Reports
3102 papers in training set
Top 20%
6.2%
4
EMBO reports
136 papers in training set
Top 0.4%
4.8%
5
Circulation Research
39 papers in training set
Top 0.3%
3.9%
6
Nature Communications
4913 papers in training set
Top 41%
3.5%
7
Cellular Signalling
14 papers in training set
Top 0.1%
3.5%
8
Molecular Pharmacology
15 papers in training set
Top 0.1%
3.5%
50% of probability mass above
9
Journal of Biological Chemistry
641 papers in training set
Top 0.7%
3.5%
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 26%
2.3%
11
PLOS Biology
408 papers in training set
Top 7%
2.0%
12
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.5%
1.7%
13
Cancers
200 papers in training set
Top 3%
1.5%
14
JCI Insight
241 papers in training set
Top 4%
1.5%
15
The Journal of Physiology
134 papers in training set
Top 1.0%
1.3%
16
Cell Death & Disease
126 papers in training set
Top 1%
1.3%
17
International Journal of Molecular Sciences
453 papers in training set
Top 10%
1.3%
18
PLOS ONE
4510 papers in training set
Top 61%
1.2%
19
Biochemical Pharmacology
18 papers in training set
Top 0.1%
1.2%
20
The EMBO Journal
267 papers in training set
Top 3%
1.1%
21
Journal of Molecular Biology
217 papers in training set
Top 3%
1.1%
22
Cellular and Molecular Life Sciences
84 papers in training set
Top 0.4%
0.9%
23
Frontiers in Endocrinology
53 papers in training set
Top 2%
0.9%
24
iScience
1063 papers in training set
Top 25%
0.9%
25
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.3%
0.9%
26
Biology Direct
10 papers in training set
Top 0.1%
0.9%
27
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.7%
28
PLOS Genetics
756 papers in training set
Top 15%
0.7%
29
The FEBS Journal
78 papers in training set
Top 1%
0.6%
30
F1000Research
79 papers in training set
Top 6%
0.6%